In 2020, the global peripheral vascular device market size was valued at $11.9 billion, with over 16 million yearly peripheral vascular procedures performed. The market size is expected to increase at a compound annual growth rate (CAGR) of 5.2% to reach $16.9 billion in 2026. Throughout this medical market research, we analyzed 113 peripheral vascular

In 2022, the European Peripheral Vascular Devices Market was valued at around €1.5 billion, and it is projected to grow at a CAGR of 3.1% during the forecast period. As a result, it is anticipated to reach approximately €1.9 billion. Throughout this medical device market research, we analyzed over 50 companies within the peripheral vascular

The full report suite on the U.S. market for peripheral vascular devices includes peripheral vascular stents, percutaneous transluminal angioplasty (PTA) balloon catheters, drug-coated balloons (DCBs), atherectomy devices, intravascular lithotripsy, chronic total occlusion (CTO) devices, surgical grafts, stent grafts, embolic protection devices (EPDs), peripheral thrombus management devices, inferior vena cava filters (IVCFs) and retrieval devices, carotid shunts, transcarotid arterial revascularization (TCAR) flow reversal systems and stents, diagnostic and interventional catheters, diagnostic and interventional guidewires, introducer sheaths, vascular closure devices (VCDs), transcatheter embolization devices and peripheral IVUS catheters.

This global market research includes 0.014”-0.035” balloons, high-pressure balloons, large balloons greater than 12mm in diameter and specialty balloons. Specialty balloons include cryoplasty balloons, cutting balloons, scoring balloons and other balloons. The analysis also include DCBs used in the superficial femoral artery (SFA) and in AV access procedures.

Drug-coated balloons have emerged as a promising technology for treating peripheral arterial disease (PAD). These devices are similar to traditional balloon dilation catheters, but feature a drug coating designed to combat restenosis. As of January 2018, DCBs are approved in the United States for use in treating lesions of the superficial femoral artery (SFA) and in AV access procedures. However, several companies are in the process of obtaining approval for BTK use of DCBs.